Secukinumab-Induced Lymphocytic Colitis

Secukinumab an interleukin-17 (IL-17) monoclonal antibody inhibitor is currently approved for the treatment of rheumatological conditions, such as psoriasis and ankylosing spondylitis. Lymphocytic colitis, a phenotype of microscopic colitis, is a long-term inflammatory condition, is characterized by...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandu, Siva Santosh Kumar, Khan, Mohammad Hassaan, Vasikaran, Anush, Pandit, Sudha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272475/
https://www.ncbi.nlm.nih.gov/pubmed/35801542
http://dx.doi.org/10.1177/23247096221110399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272475/
https://www.ncbi.nlm.nih.gov/pubmed/35801542
http://dx.doi.org/10.1177/23247096221110399

Ejemplares similares